Lappaconitine

Lappaconitine is a diterpenoid alkaloid extracted from Aconitum sinomontanum that exerts analgesic and anti-inflammatory effects primarily through sodium channel blockade and suppression of pro-inflammatory cytokine cascades. It has been studied in both animal pain models and limited clinical settings, particularly for inflammatory conditions requiring cytokine modulation.

Origin & History

Lappaconitine is a C18-diterpenoid alkaloid extracted from plants in the Aconitum genus, traditionally used in herbal medicine. It is a non-addictive alkaloid compound that can be administered through various routes including oral, intraperitoneal, and intrathecal administration.

Historical & Cultural Context

While lappaconitine is derived from Aconitum species used in traditional medicine, the research dossier does not provide specific historical or cultural context. Traditional uses and historical applications remain undocumented in the provided sources.

Health Benefits

• Pain relief: Animal studies (PMID 41725249, 12928109) showed significant reduction in writhing episodes at 1-4 mg/kg doses in mice pain models (preliminary evidence)
• Anti-inflammatory effects: Clinical data showed reduced inflammatory markers (TNF-α, hs-CRP, IL-1, IL-6) when combined with CRRT in ICU sepsis patients (limited human evidence)
• Neuropathic pain management: Rat studies (PMID 29926144) demonstrated dose-dependent antiallodynia and antihyperalgesia with ED₅₀ values of 1.1-1.6 mg/kg (preliminary evidence)
• Opioid-sparing effects: Limited human data suggests 16 mg doses reduced morphine requirements and adverse reactions in combination therapy (preliminary clinical evidence)
• Antidiarrheal properties: Mouse studies showed prolonged diarrheal onset time in castor oil-induced models at 1-4 mg/kg doses (preliminary evidence)

How It Works

Lappaconitine blocks voltage-gated sodium channels (Nav1.7, Nav1.8) on peripheral nociceptors, reducing action potential propagation and dampening pain signal transmission. It also suppresses NF-κB pathway activation, thereby downregulating transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Additionally, lappaconitine may interact with opioid receptors as a partial modulator, contributing to its central analgesic component observed in rodent models.

Scientific Research

Research consists primarily of preclinical animal studies including pain models in mice (PMID 41725249, 12928109) and inflammatory pain studies in rats (PMID 36295824, 9606904). Limited human clinical data exists, with one study showing efficacy at 16 mg doses for reducing morphine requirements, though comprehensive human RCTs and meta-analyses are lacking.

Clinical Summary

Animal studies (PMID 41725249, PMID 12928109) demonstrated significant dose-dependent reductions in acetic acid-induced writhing episodes in mice at doses of 1–4 mg/kg, providing preliminary mechanistic evidence for analgesic activity. Clinical data examining lappaconitine combined with continuous renal replacement therapy (CRRT) showed measurable reductions in inflammatory markers including TNF-α, hs-CRP, IL-1, and IL-6, though these studies are limited in sample size and often confounded by co-interventions. The overall evidence base remains preliminary, with no large-scale randomized controlled trials establishing efficacy or optimal dosing in humans. Extrapolation of rodent dosing to human supplementation contexts is not currently supported by the available literature.

Nutritional Profile

Lappaconitine is a diterpenoid alkaloid compound isolated from the roots of Aconitum sinomontanum and related Aconitum species. It is not a nutrient but a bioactive secondary metabolite characterized by a complex norditerpenoid skeleton, functioning as a sodium channel modulator with analgesic and anti-inflammatory properties at low milligram-per-kilogram doses.

Preparation & Dosage

Animal studies used 1-8 mg/kg body weight orally or by injection. Limited human data suggests 16 mg as combination therapy showed best outcomes. No standardized human dosing guidelines are established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Diclofenac sodium, loperamide, morphine (medical supervision required), CRRT therapy (clinical setting)

Safety & Interactions

Lappaconitine, like other aconitine-derived alkaloids, carries a cardiotoxicity risk at elevated doses, including potential for arrhythmias and QT interval prolongation, which necessitates caution during use. It may potentiate the effects of antiarrhythmic drugs (e.g., amiodarone, lidocaine) and other sodium channel blockers, creating dangerous additive effects on cardiac conduction. Concomitant use with anticoagulants or NSAIDs has not been formally studied but warrants caution given overlapping inflammatory pathway modulation. Lappaconitine is contraindicated in pregnancy due to the known teratogenic and toxic potential of Aconitum-derived alkaloids, and it should not be used without medical supervision.